Literature DB >> 19783262

Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.

Carmen Alemán1, José Manuel Porcel, Rosa Ma Segura, José Alegre, Aureli Esquerda, Eva Ruiz, Silvia Bielsa, Tomás Fernández de Sevilla.   

Abstract

BACKGROUND: Malignant mesothelioma (MM) is a highly aggressive tumor that can be difficult to diagnose, resulting in a delayed diagnosis in some cases. Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in the diagnosis of MM. PATIENTS AND METHODS: Pleural fluid SMRP concentration was measured in 68 patients: 47 had malignant pleural effusions (18 MM and 29 metastatic effusion) and 21 had benign pleural effusion (8 infectious disease and 13 idiopathic effusion). Mann-Whitney analysis was used to compare SMRP values according to the etiology of the effusion.
RESULTS: Pleural fluid SMRP concentration was significantly higher in patients with malignant pleural effusion than in those with benign effusion (P=0.02). When malignant pleural effusions were analyzed separately, MM patients had the highest median pleural fluid SMRP concentration, with significant differences as compared to patients with idiopathic pleural effusion.
CONCLUSIONS: Soluble mesothelin-related peptide measurement in pleural fluid may aid in the diagnosis of patients presenting with pleural effusion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783262     DOI: 10.1016/j.medcli.2008.11.047

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  3 in total

1.  Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Authors:  Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

2.  Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Authors:  Jenette Creaney; Amanda Segal; Nola Olsen; Ian M Dick; A W Bill Musk; Steven J Skates; Bruce W Robinson
Journal:  Dis Markers       Date:  2014-11-23       Impact factor: 3.434

3.  Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.

Authors:  Takehiro Otoshi; Yuki Kataoka; Shunkichi Ikegaki; Emiko Saito; Hirotaka Matsumoto; Sawako Kaku; Masatoshi Shimada; Masataka Hirabayashi
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.